This week’s Immunology update highlights key advances in gene therapy, AI-enabled diagnostics, autoimmune treatments, and strategic industry partnerships shaping the future of patient care.
In Today’s Newsletter
Dive deeper
🌏 CONMED Announces Strategic Exit from Gastroenterology Product Lines [1]
Context: CONMED is exiting its gastroenterology portfolio to concentrate on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.
Key point: The company will discontinue its distribution agreement with Gore for the Gore® VIABIL® biliary stent, effective January 2026.
Implication: This strategic decision is aimed at streamlining CONMED’s operations and enhancing focus on its core markets, potentially boosting long-term growth.
💊 Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB [2]
Context: Abeona Therapeutics has launched Zevaskyn, an FDA-approved gene therapy, for treating chronic wounds in RDEB patients.
Key point: Zevaskyn is the first autologous, gene-modified cellular sheet for RDEB, offering a new option for patients previously relying on supportive care.
Implication: This milestone could significantly improve quality of life for RDEB patients and inspire future gene therapies for rare genetic diseases.
🧬 Medical Care Technologies Launches AI App for Melanoma and Wound Detection [3]
Context: Medical Care Technologies has partnered with Derm Foundation to deploy an AI-based wound and skin monitoring platform for early melanoma detection.
Key point: The app will leverage cutting-edge AI technology to identify early signs of melanoma, infections, and chronic wounds directly from a smartphone.
Implication: This could revolutionize early detection, making it more accessible and affordable, especially in underserved areas.
🎯 Navigator Medicines Completes Phase 1b Trial of NAV-240 for Hidradenitis Suppurativa [4]
https://www.dermatologytimes.com/view/phase-1b-trial-completed-for-potential-hs-therapy-nav-240
Context: NAV-240, a bispecific antibody targeting OX40L and TNFα, has completed its Phase 1b trial, showing promising safety and pharmacokinetics data.
Key point: The trial demonstrated good tolerability and could pave the way for more effective HS treatments.
Implication: With no serious adverse events, NAV-240 could surpass current TNFα therapies in treating hidradenitis suppurativa.
☢️ Novartis Partners with AI Biotech Relation in $1.7B Deal [5]
https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech
Context: Novartis has entered a multi-program partnership with Relation, a British biotech utilizing AI to discover novel targets for immuno-dermatology diseases.
Key point: The deal includes up to $1.7 billion in potential payments, focusing on atopic disease targets.
Implication: This collaboration could significantly accelerate drug discovery in immuno-dermatology, enhancing Novartis’ existing portfolio.
🧠 OSE Immunotherapeutics Amends Partnership with AbbVie on ABBV-230 [6]
Context: OSE Immunotherapeutics will now lead the early-stage development of ABBV-230, a monoclonal antibody aimed at resolving chronic inflammation.
Key point: AbbVie retains commercialization rights post-Phase 1, but OSE takes charge of the preclinical and Phase 1 studies.
Implication: This change could accelerate ABBV-230’s progress, leveraging OSE’s immunology expertise for early development.
💉 Iolyx Therapeutics Forms Agreement with Laboratoires Théa for ILYX-002 [7]
Context: Iolyx Therapeutics has secured a partnership with Laboratoires Théa for the development and commercialization of ILYX-002, targeting autoimmune dry eye disease.
Key point: Théa will handle Phase 3 trials and marketing in key regions, while Iolyx focuses on manufacturing and non-clinical activities.
Implication: This agreement could speed up the development of ILYX-002, potentially improving treatment for patients with autoimmune-related dry eye disease.
🔬 Orna Therapeutics Presents Data on In Vivo CAR Programs for Autoimmune Diseases and Oncology [8]
Context: Orna Therapeutics showcased promising preclinical data for its in vivo CAR T-cell therapies at the 2025 ASH meeting, targeting autoimmune diseases and BCMA-related cancers.
Key point: The therapies showed targeted depletion of B cells and plasma cells, demonstrating robust efficacy in preclinical models.
Implication: Orna’s innovative CAR T-cell therapies could provide new treatments for autoimmune diseases and cancers with fewer side effects.
🧬 Fate Therapeutics Updates Phase 1 Data for FT819 in Lupus and Other Autoimmune Diseases [9]
Context: Fate Therapeutics presented updated data for FT819, an off-the-shelf CAR T-cell therapy, showing durable responses in lupus patients.
Key point: The therapy demonstrated a significant decrease in disease activity and a favorable safety profile with no serious adverse events.
Implication: FT819 could provide a scalable, on-demand solution for autoimmune diseases, with potential for broad accessibility.
Why it matters
- CONMED’s exit from gastroenterology [1] reflects a shift to a more focused strategy in surgical innovations, potentially boosting long-term growth.
- Abeona’s Zevaskyn launch [2] is a major milestone in gene therapy for rare skin conditions, improving quality of life for RDEB patients.
- Medical Care Technologies’ AI app [3] could democratize melanoma detection, improving early diagnosis in underserved communities.
- NAV-240 [4] could revolutionize hidradenitis suppurativa treatment, potentially offering better efficacy than current therapies.
- Novartis and Relation’s partnership [5] highlights the role of AI in advancing immuno-dermatology, with far-reaching implications for patient care.
- OSE Immunotherapeutics’ strategic shift [6] could accelerate ABBV-230’s development, enhancing its potential as a treatment for chronic inflammation.
- The agreement between Iolyx and Théa [7] brings hope for improved treatments for autoimmune dry eye disease.
- Orna’s CAR therapies [8] represent a promising future for treating autoimmune diseases and cancers more efficiently.
- Fate Therapeutics’ FT819 [9] offers a promising, scalable treatment for lupus and other autoimmune diseases.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Immunology archive on our research hub page.
FAQ
What does CONMED’s exit mean for the company?
CONMED’s strategic exit will streamline operations and enhance focus on its core surgical markets, potentially boosting future growth [1].
How does Zevaskyn benefit RDEB patients?
Zevaskyn offers a breakthrough treatment for RDEB, providing durable wound healing without the need for immunosuppressive drugs [2].
What is the potential impact of Medical Care Technologies’ AI app?
The app could offer a low-cost, accessible solution for early melanoma detection, transforming skin disease management in underserved regions [3].
How effective is NAV-240 for hidradenitis suppurativa?
NAV-240 demonstrated good safety and tolerability in Phase 1b, offering a potential breakthrough for treating hidradenitis suppurativa [4].
What is Novartis aiming to achieve with Relation?
The partnership aims to leverage AI to discover new immuno-dermatology targets, accelerating drug development for atopic diseases [5].
What is the significance of OSE Immunotherapeutics’ strategic change?
OSE’s lead in early development for ABBV-230 could accelerate its progress toward treating chronic inflammation, unlocking new therapeutic options [6].
What does the Iolyx-Théa partnership mean for dry eye treatment?
The partnership could expedite the development of ILYX-002, providing an effective treatment for autoimmune dry eye disease [7].
What’s Orna Therapeutics’ approach to CAR therapies?
Orna’s in vivo CAR therapies offer targeted treatment for autoimmune diseases and cancers, with fewer side effects [8].
What makes Fate Therapeutics’ FT819 unique?
FT819 is an off-the-shelf CAR T-cell therapy that provides scalable and accessible treatment for autoimmune diseases like lupus [9].
Entities / Keywords
CONMED, gastroenterology exit, minimally invasive surgery, surgical portfolio.
Abeona, Zevaskyn, RDEB, gene therapy.
Medical Care Technologies, AI, melanoma detection, skin wounds.
Navigator Medicines, NAV-240, hidradenitis suppurativa, bispecific antibody.
Novartis, Relation, immuno-dermatology, AI-driven drug discovery.
OSE Immunotherapeutics, AbbVie, ABBV-230, chronic inflammation.
Iolyx Therapeutics, Laboratoires Théa, ILYX-002, autoimmune dry eye disease.
Orna Therapeutics, in vivo CAR, autoimmune diseases, oncology.
Fate Therapeutics, FT819, CAR T-cell, lupus, autoimmune diseases.
References
- https://www.businesswire.com/news/home/20251205036683/en/CONMED-Corporation-Announces-Strategic-Exit-from-Gastroenterology-Product-Lines
- https://www.dermatologytimes.com/view/abeona-initiates-first-commercial-treatment-of-zevaskyn-for-rdeb
- https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/medical-care-technologies-otc-pink-mdce-positions-itself-in-the-multi-1115374
- https://www.dermatologytimes.com/view/phase-1b-trial-completed-for-potential-hs-therapy-nav-240
- https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech
- https://www.globenewswire.com/news-release/2025/12/08/3201201/0/en/ose-immunotherapeutics-announces-strategic-amendment-to-abbvie-s-partnership-on-abbv-230-development.html
- https://www.globenewswire.com/news-release/2025/12/03/3198729/0/en/Iolyx-Therapeutics-Enters-Strategic-Agreement-with-Laboratoires-Th%C3%A9a-to-Develop-and-Commercialize-ILYX-002-intended-for-the-Treatment-of-Autoimmune-Associated-Dry-Eye-Disease-and-S.html
- https://www.wric.com/business/press-releases/cision/20251207NY40901/orna-therapeutics-presents-new-data-supporting-its-in-vivo-car-programs-for-autoimmune-diseases-and-oncology-at-the-67th-american-society-of-hematology-annual-meeting/
- https://www.globenewswire.com/news-release/2025/12/08/3201474/24675/en/Fate-Therapeutics-Presents-Updated-Phase-1-Clinical-Data-of-FT819-Off-the-shelf-CAR-T-cell-Product-Candidate-for-Systemic-Lupus-Erythematosus-and-Preclinical-Advances-in-Next-Generational-Programs